Endothelial cell compatibility of clarithromycin for intravenous use

C. Armbruster, H. Vorbach, B. Robibaro (Vienna, Austria)

Source: Annual Congress 2006 - Miscellaneous respiratory infections I
Session: Miscellaneous respiratory infections I
Session type: Electronic Poster Session
Number: 4205

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Armbruster, H. Vorbach, B. Robibaro (Vienna, Austria). Endothelial cell compatibility of clarithromycin for intravenous use. Eur Respir J 2006; 28: Suppl. 50, 4205

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Endothelial cell compatibility of azithromycin and erythromycin
Source: Eur Respir J 2004; 24: Suppl. 48, 186s
Year: 2004

Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006

Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP)
Source: Eur Respir J 2001; 18: Suppl. 33, 137s
Year: 2001

Stability of a new formulation of intravenous epoprostenol sodium
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012


Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules
Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019
Year: 2019



Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015

No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo
Source: Eur Respir J 2003; 22: Suppl. 45, 335s
Year: 2003

Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin
Source: Eur Respir J, 55 (5) 1901903; 10.1183/13993003.01903-2019
Year: 2020



Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011

Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis.
Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease
Year: 2021


Comparison of the adherence of the oral pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid 2,000/125 mg twice daily with that of the standard formulation of amoxicillin/clavulanic acid 500/125 mg thrice daily
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Systemic bioavailability of inhaled corticosteroids: appropriate and comparable methodology
Source: Eur Respir J 2001; 18: 246
Year: 2001


Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy
Source: Eur Respir Rev 2008; 17: 41-42
Year: 2008



Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy
Source: Eur Respir J 2007; 30: Suppl. 51, 713s
Year: 2007

Anti-inflammatory properties of nimesulide and clarithromycin: a comparative study during the therapy of bronchial sepsis involving P.aeruginosa
Source: Eur Respir J 2002; 20: Suppl. 38, 373s
Year: 2002

Inhaled corticosteroids reduce senescence in endothelial progenitor cells from COPD patients
Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases
Year: 2021



Angiogenic sepsis in intravenous drug abusers
Source: Eur Respir J 2003; 22: Suppl. 45, 451s
Year: 2003

The inhibitory effect of ciprofloxacin on bacterial adhesiveness is enhanced by the SH-metabolite I of erdosteine (mucolytic drug)
Source: Eur Respir J 2001; 18: Suppl. 33, 543s
Year: 2001

Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012


Effectiveness and safety of gatifloxacin in patients with drug resistance tuberculosus befor unsuccessfully treated with ofloxacin and ciprofloxacin
Source: Eur Respir J 2006; 28: Suppl. 50, 588s
Year: 2006